Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Propanc Biopharma Inc PPCB

Healthcare Biotechnology
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from... see more

Recent & Breaking News (OTCPK:PPCB)

Propanc Biopharma Completes Successful Reproduction Run for PRP

PR Newswire March 14, 2018

Propanc Biopharma Receives Allowance of Key Patent Application in the EU

PR Newswire February 20, 2018

Propanc Biopharma Provides Shareholder Update and Goals for 2018

PR Newswire February 12, 2018

Propanc Biopharma Engages Alan Morell of Creative Management Partners as Senior Strategic Advisor to CEO and Board of Directors

PR Newswire January 10, 2018

Propanc Biopharma Repays Magna Invests Senior Secured Convertible Debentures

PR Newswire January 5, 2018

Propanc Biopharma to Present at the 10th Annual Biotech Showcase™ 2018

PR Newswire December 28, 2017

Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials

PR Newswire December 4, 2017

Propanc Biopharma to Present at the 10th Annual LD Micro Main Event

MarketWire Canada November 27, 2017

Propanc Biopharma Submits Orphan Drug Designation Request to the US Food and Drug Administration for Treatment of Ovarian Cancer

Marketwired October 25, 2017

Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Marketwired October 19, 2017

Propanc Biopharma Highlights Therapeutic Potential of PRP

Marketwired September 27, 2017

Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies

MarketWire Canada August 30, 2017

UPDATE - Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Marketwired August 2, 2017

Company Prepares Orphan Drug Designation Application to FDA for Treatment of Ovarian Cancer

MarketWire Canada August 2, 2017

Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP

Marketwired July 27, 2017

Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China

MarketWire Canada July 20, 2017

Propanc Biopharma Announces Joint Research Partnership with Jaen University, Spain

MarketWire Canada July 18, 2017

Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

MarketWire Canada June 26, 2017

Propanc Biopharma Makes Significant Progress with PCT Patent Application

MarketWire Canada June 9, 2017

Propanc Biopharma Changes Ticker Symbol to "PPCB"

MarketWire Canada June 1, 2017